- Home
- SERA vs CLYM Comparison
SERA vs CLYM Comparison
Compare SERA & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- CLYM
- Stock Information
- Founded
- SERA 2008
- CLYM 2018
- Country
- SERA United States
- CLYM United States
- Employees
- SERA N/A
- CLYM N/A
- Industry
- SERA Precision Instruments
- CLYM
- Sector
- SERA Health Care
- CLYM
- Exchange
- SERA Nasdaq
- CLYM NYSE
- Market Cap
- SERA 87.4M
- CLYM 79.1M
- IPO Year
- SERA 2021
- CLYM 2021
- Fundamental
- Price
- SERA $1.70
- CLYM $1.29
- Analyst Decision
- SERA
- CLYM
- Analyst Count
- SERA 0
- CLYM 0
- Target Price
- SERA N/A
- CLYM N/A
- AVG Volume (30 Days)
- SERA 268.4K
- CLYM 145.8K
- Earning Date
- SERA 05-07-2025
- CLYM 05-14-2025
- Dividend Yield
- SERA N/A
- CLYM N/A
- EPS Growth
- SERA N/A
- CLYM N/A
- EPS
- SERA N/A
- CLYM N/A
- Revenue
- SERA $115,000.00
- CLYM N/A
- Revenue This Year
- SERA $390.13
- CLYM N/A
- Revenue Next Year
- SERA $440.54
- CLYM N/A
- P/E Ratio
- SERA N/A
- CLYM N/A
- Revenue Growth
- SERA N/A
- CLYM N/A
- 52 Week Low
- SERA $1.53
- CLYM $1.05
- 52 Week High
- SERA $9.37
- CLYM $9.58
- Technical
- Relative Strength Index (RSI)
- SERA 32.94
- CLYM N/A
- Support Level
- SERA $1.53
- CLYM N/A
- Resistance Level
- SERA $2.47
- CLYM N/A
- Average True Range (ATR)
- SERA 0.19
- CLYM 0.00
- MACD
- SERA 0.02
- CLYM 0.00
- Stochastic Oscillator
- SERA 18.18
- CLYM 0.00
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.